Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma

Lung Cancer

Volumn 32, Issue 2, 2001, Pages 189-196

  Gajra, Ajeet ^a   Mehdi, Syed A ^a   Kirshner, Jeffery ^c   Newman, Nancy ^a   Graziano, Stephen L ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b SYRACUSE VA MEDICAL CENTER   (United States)

^c Hematology/Oncology Associates of Central New York   (United States)

Author keywords

Carboplatin; Gemcitabine; Non small cell lung carcinoma; Phase I clinical trial

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FATIGUE; FEMALE; HUMAN; HYPONATREMIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPONATREMIA; LIFE TABLES; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NERVOUS SYSTEM DISEASES; NEUTROPENIA; REMISSION INDUCTION; SURVIVAL ANALYSIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0035029432     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00213-0     Document Type: Article

References (25)

1. Cancer statistics
2. Chemotherapy of lung cancer
3. Chemotherapy for advanced non small cell lung cancer: How much benefit is enough?
4. Chemotherapy of non-small cell bronchial cancers. Meta-analysis of the literature as a function of the extent of disease
5. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience
6. Interaction between cisplatin and gemcitabine in vitro and in vivo
7. Efficacy and safety profile of gemcitabine in NSCLC: A phase II study
8. Single agent activity of weekly gemcitabine in advanced NSCLC: A phase II study
9. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
10. Paclitaxel with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis
11. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
12. A randomized study comparing cisplatin or carboplatin with etoposide in patients with NSCLC: European Organization for Research and Treatment of Cancer Protocol 07861
13. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
14. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small -cell lung cancer: A randomized phase III study of Italian Lung Cancer Project
15. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
16. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
17. Carboplatin (CARBO) in combination with gemcitabine(GEM) in advanced non small cell lung cancer. Comparison of two consecutive trials using different schedules
18. Sequential carboplatin/gemcitabine→paclitaxel in advanced non-small cell lung cancer: an effective and well tolerated regimen
19. A combination therapy of gemcitabine and carboplatin in advanced stage non small cell lung carcinoma
20. A phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small cell lung cancer
21. First-line therapy with gemcitabine and carboplatin in patients with advanced non small cell lung cancer: a phase II study
22. Phase II trial of gemcitabine and carboplatin in advanced non small cell lung cancers
23. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell cancer (NSCLC): a Hoosier Oncology Group study
24. A phase II study of gemcitabine plus carboplatin in chemo-naive patients with advanced non small cell lung cancer
25. Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer